AKT1 and metastatic melanoma: Nevertheless, combining TKIs and immunotherapies targeting key proteins in the oncogenic RAS/RAF/MAPK or PI3K/AKT pathways has been shown to delay the onset of resistance, resulting in improved progression-free survival in patients with metastatic melanoma (Table 1) [13,14].